Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fresenius SE & Co. KGaA (DE:FRE)
XETRA:FRE
RESEARCH TOOLSreports
Holding DE:FRE?
Track your performance easily
FRE Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€24.32 - €36.24
Previous Close€32.21
Volume500.14K
Average Volume (3M)904.97K
Market Cap
€18.27B
Enterprise Value€55.49B
Total Cash (Recent Filing)€2.35B
Total Debt (Recent Filing)€27.76B
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 26, 2025EPS Estimate
€0.78Last Dividend Ex-Date
May 18, 2023Dividend Yield2.81%
Share Statistics
EPS (TTM)-0.68
Shares Outstanding563,237,277
10 Day Avg. Volume1,141,681
30 Day Avg. Volume904,973
Standard Deviation0.09
R-Squared0.21
Alpha-0.00028
Financial Highlights & Ratios
Price to Book (P/B)3.56
Price to Sales (P/S)0.37
Price to Cash Flow (P/CF)2.10
P/FCF Ratio3.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.08Price Target Upside22.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Fresenius SE & Co. KGaA News
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
10.75% Mutual Funds
― Other Institutional Investors
80.40% Public Companies and
Individual Investors
FRE FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest stock price was €24.32 and its highest was €36.24 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Currently, no data Available
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Mar 26, 2025 which is in 124 days.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Fresenius SE & Co. KGaA released its earnings results on Nov 06, 2024. The company reported €0.69 earnings per share for the quarter, beating the consensus estimate of €0.654 by €0.036.
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA pays a Semiannually dividend of €0.92 which represents an annual dividend yield of 2.81%. See more information on Fresenius SE & Co. KGaA dividends here
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is €0.78.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Fresenius SE & Co. KGaA reported an EPS of €0.69 in its last earnings report, beating expectations of €0.654. Following the earnings report the stock price went up 2.661%.
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FRE
---
Fresenius SE & Co. KGaA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.98%
12-Months-Change
Fundamentals
Return on Equity
3.13%
Trailing 12-Months
Asset Growth
-43.76%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE is a healthcare holding company based in Germany with four segments. The company owns a large stake in dialysis service provider and equipment manufacturer Fresenius Medical Care, which accounted for 49% of consolidated revenue in 2019. The Kabi segment (19% of revenue) manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. At 26% of revenue, the Helios segment operates private hospitals in Germany, Spain, and Latin America. At 6% of revenue, Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.
---
FRE Stock 12 Month Forecast
Average Price Target
€40.08
▲(22.87% Upside)
Technical Analysis
Fresenius SE & Co. KGaA
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
HUTCHMED (China) Limited
―
Best Analysts Covering FRE
1 Year
1 Year Success Rate
17/21 ratings generated profit
1 Year Average Return
+11.83%
reiterated a buy rating 15 days ago
Copying Victoria Lambert's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +11.83% per trade.
---